Skip to main content
logo
Arcus Biosciences logo
Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
22.51
-1.83 (-7.52%)
Oct 13, 2026, 4:00 PM EDT - Market closed

Arcus Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
117247258117112383
Revenue Growth
-55.34%-4.26%120.51%4.46%-70.76%391.03%
Gross Profit
-380-276-190-223-176126
Operating Income
-486-386-310-340-28054
Net Income
-460-353-283-307-26753
Earnings Per Share
-3.86-3.29-3.14-4.15-3.710.71
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
7751,0109928661,138681
Total Debt
238219180140120117
Net Cash (Debt)
5377918127261,018564
Net Cash Growth
-32.62%-2.59%11.85%-28.68%80.50%-20.94%
Net Cash Per Share
4.517.369.019.8114.147.62

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-474-482-170-306438-256
Capital Expenditures
-1-2-6-24-6-26
Free Cash Flow
-475-484-176-330432-282
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--111.74%-73.64%-190.60%-157.14%32.90%
Operating Margin
-415.39%-156.28%-120.15%-290.60%-250.00%14.10%
Pretax Margin
-393.16%-142.91%-109.30%-257.26%-237.50%14.36%
Profit Margin
-393.16%-142.91%-109.69%-262.39%-238.39%13.84%
FCF Margin
-405.98%-195.95%-68.22%-282.05%385.71%-73.63%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----53.64
Forward PE
-13.1113.1113.1113.1113.11
P/FCF Ratio
----3.47-
PS Ratio
24.5011.945.2812.2213.377.42